Skip to main content

Gyre Therapeutics, Inc.

corporate_fare Company Profile

Gyre Therapeutics, Inc.

GYRE·NASDAQ·Life Sciences·CIK 0001124105

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and sells small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (doing business as Gyre Pharmaceuticals Co., Ltd.), in the People's Republic of China (PRC), and through its U.S. operations based in San Diego, California. In the PRC, Gyre Therapeutics has developed and commercialized ETUARY® (pirfenidone) for fibrotic diseases, which has generated consistent revenue and established the company as a leading participant in treating pulmonary fibrosis. The company has expanded into the United States to advance the clinical development of its pipeline, including F351 (Hydronidone), its lead product candidate for liver fibrosis. Gyre Therapeutics' strategy involves using its existing commercial portfolio to support and reduce risk for late-stage product candidates, extending approved products to treat additional conditions, and creating a diverse pipeline for significant unmet medical needs in fibrosis and related inflammatory diseases. On March 2, 2026, Gyre Therapeutics entered into a Merger Agreement with Cullgen Inc. and Helix Merger Sub Corp., a wholly owned subsidiary of Gyre, under which Merger Sub will merge with Cullgen, with Cullgen becoming a wholly owned subsidiary of Gyre.

Gyre Therapeutics, Inc. (NASDAQ:GYRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for GYRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for GYRE spans 8-K, 10-Q, 8-K/A, S-3.

Recent high-impact activity:

  • Gyre Q3 Revenue $32.9M, Swings to $2.5M Loss; F351 NMPA Decision Due by 1Q27
  • Q3 Revenue Climbs to $32.9M as ETUARY Sales Grow, 2026 Outlook Reaffirmed
  • Gyre Posts Q2 Revenue of $29.1M, Reaffirms Full-Year Outlook, and Flags GNI Japan Share Pledge
  • Gyre Therapeutics Posts Q2 2026 Revenue of $29.1M, Reaffirms Full-Year Outlook, and Spotlights F351 NDA Acceptance
  • Gyre Therapeutics Amends 8-K to Include Cullgen Financials and Pro Forma Statements

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$116.59M
Net Income
$9.88M
Diluted EPS
$0.02
Op. Cash Flow
$1.01M
Free Cash Flow
-$180K
Gross Profit
$111.17M
Operating Income
$11.49M
Cash & Equivalents
$37.07M
Debt / Equity
0.00×
Net Margin
8.5%
Shares Outstanding
91.31M sh
Source: 10-K · filed 2026-03-13 · accession 0001193125-26-106251

Short Interest & Short Volume

14.22 days to cover

FINRA reported short interest of 2,241,208 shares in GYRE as of the October 30, 2026 settlement, a 16.3% increase from the prior period — about 14.2 days to cover at its recent average daily volume. On November 20, 2026, 76.8% of GYRE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,241,208 shares as of October 30, 2026
Change vs prior period▲ 16.3%
Days to cover14.22 at avg daily volume of 157,556
Daily short volume (FINRA facilities)76.8% of 67,903 shares on November 20, 2026
5-day average short volume62.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for GYRE, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.

1 shelf registration

Resale Registration Filed · Shares from Cullgen Acquisition

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with G →
$4.27 +1.43% today
52-week range · as of 2026-11-05 $3.97 – $9.14
Market cap
$485.5M
Volume
240.1K (1.1× avg)
3-mo avg 215K
Live data · 2026-11-22 11:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GYRE - Latest Insights

GYRE
Nov 05, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $4.27 info
Change: +$0.260 (+6%) info
Market Cap: $485.501M info
GYRE
Nov 05, 2026, 4:07 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $4.27 info
Change: +$0.260 (+6%) info
Market Cap: $485.501M info
GYRE
Aug 07, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.67
Real-time Price: $4.27 info
Change: -$2.40 (-36%) info
Market Cap: $485.501M info
GYRE
Aug 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.40
Real-time Price: $4.27 info
Change: -$2.13 (-33%) info
Market Cap: $485.501M info
GYRE
Jul 15, 2026, 5:09 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $6.56
Real-time Price: $4.27 info
Change: -$2.29 (-35%) info
Market Cap: $485.501M info
GYRE
Jun 22, 2026, 7:16 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $6.34
Real-time Price: $4.27 info
Change: -$2.07 (-33%) info
Market Cap: $485.501M info
GYRE
Jun 16, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.80
Real-time Price: $4.27 info
Change: -$1.53 (-26%) info
Market Cap: $485.501M info
GYRE
May 14, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.00
Real-time Price: $4.27 info
Change: -$2.73 (-39%) info
Market Cap: $485.501M info
GYRE
May 12, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $7.30
Real-time Price: $4.27 info
Change: -$3.03 (-42%) info
Market Cap: $485.501M info
GYRE
May 12, 2026, 5:03 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.30
Real-time Price: $4.27 info
Change: -$3.03 (-42%) info
Market Cap: $485.501M info
GYRE
May 11, 2026, 7:10 AM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $7.47
Real-time Price: $4.27 info
Change: -$3.20 (-43%) info
Market Cap: $485.501M info
GYRE
May 08, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.47
Real-time Price: $4.27 info
Change: -$3.20 (-43%) info
Market Cap: $485.501M info
GYRE
May 07, 2026, 6:01 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $7.97
Real-time Price: $4.27 info
Change: -$3.70 (-46%) info
Market Cap: $485.501M info
GYRE
May 06, 2026, 9:53 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $8.04
Real-time Price: $4.27 info
Change: -$3.77 (-47%) info
Market Cap: $485.501M info
GYRE
May 06, 2026, 8:46 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $8.04
Real-time Price: $4.27 info
Change: -$3.77 (-47%) info
Market Cap: $485.501M info
GYRE
May 06, 2026, 8:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.97
Real-time Price: $4.27 info
Change: -$3.70 (-46%) info
Market Cap: $485.501M info
GYRE
May 04, 2026, 9:13 AM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $7.85
Real-time Price: $4.27 info
Change: -$3.58 (-46%) info
Market Cap: $485.501M info
GYRE
May 04, 2026, 9:12 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.85
Real-time Price: $4.27 info
Change: -$3.58 (-46%) info
Market Cap: $485.501M info
GYRE
May 04, 2026, 8:47 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $7.85
Real-time Price: $4.27 info
Change: -$3.58 (-46%) info
Market Cap: $485.501M info
GYRE
Apr 27, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $7.63
Real-time Price: $4.27 info
Change: -$3.36 (-44%) info
Market Cap: $485.501M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets